Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -236.93M | -236.30M | -252.09M | -258.06M | -243.79M |
| Total Depreciation and Amortization | 208.00K | 356.00K | 489.00K | 630.00K | 631.00K |
| Total Amortization of Deferred Charges | 1.21M | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.51M | 32.12M | 35.98M | 39.48M | 37.58M |
| Change in Net Operating Assets | -437.00K | -5.00M | 19.95M | 18.52M | 22.64M |
| Cash from Operations | -206.44M | -208.83M | -195.68M | -199.43M | -182.94M |
| Capital Expenditure | 0.00 | -16.00K | 0.00 | 0.00 | -775.00K |
| Sale of Property, Plant, and Equipment | 218.00K | 171.00K | 84.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 168.30M | 26.92M | 132.66M | 123.60M | -69.78M |
| Cash from Investing | 168.52M | 27.08M | 132.75M | 123.60M | -70.56M |
| Total Debt Issued | 57.16M | 18.26M | 18.40M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.93M | 15.41M | 17.16M | 19.76M | 21.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 225.00K | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 77.09M | 33.89M | 35.56M | 19.76M | 21.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.17M | -147.86M | -27.37M | -56.07M | -231.89M |